Race Oncology Limited (“Race”) announces Executive Director and Chief Scientific Officer (CSO), Dr Daniel Tillett has advised his decision to step down from his roles. Dr Tillett will provide ongoing support through June 2023 to ensure a smooth transition of…
Race is pleased to announce the appointment of global pharmaceutical and commercial leader, Mr Damian Clarke-Bruce, as Managing Director and Chief Executive Officer, effective 1 February 2023. Mr Phil Lynch will return to his prior role as a Non-Executive Director…
Race Oncology 2022 AGM Presentation by CEO Phil Lynch and CSO Dr Daniel Tillett.
Race Oncology CEO Phillip Lynch and CSO Dr Daniel Tillett present Race’s June 2022 Quarterly Investor Briefing followed by a Q&A session.
Race Oncology CSO Dr Daniel Tillett talks to WIN Television News about Race Oncology’s research collaboration with the University of Wollongong.
